In Vitro Protein Binding of Liraglutide in Human Plasma Determined by Reiterated Stepwise Equilibrium Dialysis

التفاصيل البيبلوغرافية
العنوان: In Vitro Protein Binding of Liraglutide in Human Plasma Determined by Reiterated Stepwise Equilibrium Dialysis
المؤلفون: Lisbeth Bjerring Jensen, Jesper B. Kristensen, Anne Plum
المصدر: Journal of Pharmaceutical Sciences
بيانات النشر: Wiley Periodicals, Inc. and the American Pharmacists Association. Published by Elsevier Inc.
مصطلحات موضوعية: type 2 diabetes mellitus, Pharmaceutical Science, Plasma protein binding, protein binding, insulin detemir, Glucagon-Like Peptide 1, medicine, Humans, Hypoglycemic Agents, equilibrium dialysis, chemistry.chemical_classification, liraglutide, Liraglutide, Chemistry, in vitro method, Blood Proteins, Equipment Design, Human serum albumin, Pharmacokinetics, Pharmacodynamics and Drug Transport and Metabolism, Glucagon-like peptide-1, Blood proteins, In vitro, Ultrafiltration (renal), Diabetes Mellitus, Type 2, Biochemistry, human serum albumin, acylated peptides, Glycoprotein, Dialysis, medicine.drug, plasma proteins
الوصف: Liraglutide is a human glucagon-like peptide-1 (GLP-1) analogue approved for the treatment of type 2 diabetes. It is based on human GLP-1 with the addition of a 16-carbon fatty acid, which facilitates binding to plasma proteins, thus prolonging the elimination half-life and allowing once-daily administration. It has not been possible to quantify liraglutide protein binding by ultrafiltration (the usual method of choice), as the lipophilic molecule becomes trapped in the filter membrane. Therefore, the aim of this study was to develop a methodology that could determine the extent of liraglutide binding to plasma proteins in vitro. We report here the details of a novel reiterated stepwise equilibrium dialysis assay that has successfully been used to quantify liraglutide plasma protein binding. The assay allowed quantification of liraglutide binding to proteins in purified plasma protein solutions and human plasma samples and was effective at plasma dilutions as low as 5%. At a clinically relevant liraglutide concentration (104pM), greater than 98.9% of liraglutide was bound to protein. Specific binding to human serum albumin and α1-acid glycoprotein was 99.4% and 99.3%, respectively. The novel methodology described herein could have an application in the quantification of plasma protein binding of other highly lipophilic drug molecules. © 2013 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 102:2882–2888, 2013
اللغة: English
تدمد: 0022-3549
DOI: 10.1002/jps.23648
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f36b68b0edbd5ee676094a6df0bdc11b
Rights: OPEN
رقم الانضمام: edsair.doi.dedup.....f36b68b0edbd5ee676094a6df0bdc11b
قاعدة البيانات: OpenAIRE
الوصف
تدمد:00223549
DOI:10.1002/jps.23648